Tango Therapeutics
TNGX
121 hedge funds and large institutions have $929M invested in Tango Therapeutics in 2023 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 42 increasing their positions, 21 reducing their positions, and 16 closing their positions.
131% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 16
100% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 21
21% more funds holding
Funds holding: 100 → 121 (+21)
4.66% more ownership
Funds ownership: 87.3% → 91.96% (+4.7%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
7% less capital invested
Capital invested by funds: $1,000M → $929M (-$71.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$40M |
| 2 |
RI
RTW Investments
New York
|
+$17.1M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$14.3M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$9.33M |
| 5 |
DM
Deerfield Management
New York
|
+$6.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$25M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.1M |
| 3 |
PA
Perceptive Advisors
New York
|
-$11.3M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$9.51M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$9.39M |
TNGX Hedge Fund Activity: Q4 2023 in Review
121 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q4 2023, worth a combined $929M — down 7.1% from $1,000M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new TNGX positions and 16 closed out — a net gain of 21 holders — while 42 added to existing stakes and 21 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $40M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $25M sold.
- 121 institutional investors held Tango Therapeutics (TNGX) as of Q4 2023, up from 100 in Q3 2023.
- Funds reported $929M of Tango Therapeutics stock for Q4 2023, down 7.1% quarter-over-quarter.
- 37 funds opened new Tango Therapeutics positions in Q4 2023 and 16 closed out, a net change of +21 holders.
- The largest Tango Therapeutics buyer in Q4 2023 was EcoR1 Capital, an estimated $40M added.
- The largest Tango Therapeutics seller in Q4 2023 was Avoro Capital Advisors, an estimated $25M sold.
Based on aggregated 13F filings for Q4 2023.